ZVRA Insider Trading Activity and SEC Form 4 Filings
ZVRA insider trading summary
Over the past 12 months, insiders at Zevra Therapeutics, Inc. (ZVRA) reported 8 sales worth $1.5M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.5M.
Latest ZVRA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Neil F. McFarlane | President and CEO | Sell | $225K (20,000 @ $11.25) |
| Aug 14, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sell | $475K (42,666 @ $11.13) |
| Aug 10, 2026 | Corey Michael Watton | Director | Sell | $138K (12,300 @ $11.25) |
| Jun 22, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sell | $438K (34,557 @ $12.68) |
| May 11, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sell | $20K (1,794 @ $11.30) |
| Feb 9, 2026 | Neil F. McFarlane | President and CEO | Sell | $125K (14,625 @ $8.56) |
| Feb 3, 2026 | Joshua Schafer | CCO | Sell | $97K (10,500 @ $9.19) |
| Feb 3, 2026 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | Sell | $28K (3,000 @ $9.18) |
| Oct 10, 2025 | Neil F. McFarlane | President and CEO | Sell | $211K (19,500 @ $10.82) |
| Sep 12, 2025 | Tamara A Favorito | Director | Buy | $25K (3,175 @ $7.79) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.